Key Highlights

  • Bausch Health combines branded gastrointestinal medicines, aesthetics devices, international pharmaceuticals and the eye health leader Bausch + Lomb under one corporate umbrella.
  • Revenue per employee is influenced by Manufacturing scale, drug pricing, the large Bausch + Lomb workforce and acquisitions, so the figure should be read with its context.
  • Future results depend on Xifaxan durability, eye care growth, aesthetics expansion, Patent timelines and continued progress on managing the company's heavy Debt load.

Company Overview and Business Model

Bausch Health Companies Inc. (TSX:BHC) is a diversified healthcare company that develops, makes and sells pharmaceuticals, medical devices and eye health products. It trades on both the Toronto and New York exchanges, and the shares trade at a current share price of CAD 11.25.

The business has five reporting segments. Salix focuses on gastrointestinal drugs led by Xifaxan, Solta Medical supplies aesthetic devices, International sells pharmaceuticals and devices outside North America, Diversified Products covers mature brands, and Bausch + Lomb offers contact lenses, eye care products and surgical equipment.

For 2025 the company reported consolidated Revenue of about USD 10.27 billion, up 7%, with Salix at USD 2.58 billion, Bausch + Lomb at USD 5.10 billion and Solta Medical at USD 518 million. Adjusted EBITDA attributable to the company was USD 3.54 billion.

Its model blends high-value branded products with large-scale device and consumer eye care manufacturing, leaving a workforce split between sales, research, regulatory and plant roles across many countries.

Revenue Per Employee: A Key Measure of Operational Efficiency

Revenue per employee shows how much sales the organization generates for each person on its payroll. For a healthcare group, intellectual property, Brand strength and manufacturing automation can lift it, while labour-heavy consumer businesses pull it back.

Based on the financial year ended December 31, 2025, Bausch Health reported approximately USD 10.27 billion in total revenue and approximately 20,300 employees, about 13,000 of whom work at Bausch + Lomb. The company reports in United States dollars, and a conversion at about 1.38 Canadian dollars per United States dollar underlies the Canadian figure below.

Revenue Per Employee = Annual Revenue ÷ Total Employees

Using these figures, Bausch Health generated approximately CAD 706.63 thousand in annual revenue per employee.

Consolidated revenue includes the full Bausch + Lomb business, which is a majority-owned Subsidiary with a distinct workforce and a lower-margin product mix than the Salix drug franchise. Currency movements also change the Canadian dollar equivalent from year to year.

Acquisitions such as the Shibo aesthetics distribution business in China, divestitures and year-end headcount can shift the calculation. The ratio describes group-level productivity and is not a measure of individual output.

What Drives the Company's High Revenue Per Employee?

Several characteristics of the group explain why its revenue base is large compared with its staffing.

Branded Drug Economics: Xifaxan and other Salix products carry premium pricing, so a specialized sales force can support USD 2.58 billion of revenue.

Eye Care Scale: Bausch + Lomb manufactures contact lenses, solutions and surgical products in volume, with global distribution reaching eye care professionals and consumers.

Aesthetics Growth: Solta Medical revenue rose 18% in 2025, led by South Korea, with devices that clinics purchase and then use for recurring treatments.

Geographic Reach: Existing infrastructure in Europe, the Middle East, Africa and Asia allows new products and acquisitions to be added with limited incremental overhead.

Operating Leverage: Excluding Bausch + Lomb, the company posted its thirteenth consecutive quarter of revenue growth in mid-2026, suggesting fixed costs are being spread over rising sales.

Yet revenue efficiency does not guarantee profitability. Interest expense, legal costs, research spending and amortization remain significant, and 2025 GAAP Net Income was only USD 157 million.

Risks Investor Needs to Consider

Leverage and Refinancing: The company completed USD 9.6 billion of refinancing in 2025 and a USD 1.7 billion exchange offer, yet interest costs and maturities remain a central issue.

Product Concentration: Xifaxan accounts for a considerable share of Salix revenue, so generic competition, patent litigation or pricing pressure could affect Earnings materially.

Regulatory and Pricing Risk: Drug pricing reform, device approvals and reimbursement rules across many countries can change Economics quickly.

Legal Exposure: Pharmaceutical groups face product liability, patent and commercial disputes that can create unexpected costs.

Structural Complexity: The relationship with Bausch + Lomb, including the ownership stake and Capital allocation decisions, adds uncertainty about the group's future shape.

Weaker consumer spending on elective procedures or lenses could also reduce revenue in several segments at the same time.

What Does the ESG Investment Case Look Like?

The ESG case for Bausch Health involves patient access, product safety, manufacturing practices and the governance of a complex capital structure.

Environmental: Manufacturing sites, packaging for contact lenses and solutions, and global distribution create waste, energy and water considerations that require ongoing reduction efforts.

Social: Medicine pricing, quality control, clinical transparency and access to eye care in underserved communities influence both reputation and regulatory standing.

Governance: Board oversight of debt, litigation, related-party arrangements with Bausch + Lomb and executive incentives are central to Shareholder confidence.

Meaningful ESG progress for the group will be judged by product quality records and Balance Sheet discipline as much as by stated goals.

Latest Corporate Developments and Growth Catalysts

Second-quarter 2026 results, released on July 29, 2026, showed revenue of USD 2.85 billion, up 13% reported and 11% organic. Consolidated adjusted EBITDA attributable to the company reached USD 1,075 million, up 28%.

GAAP net income attributable to Bausch Health was USD 258 million, or USD 0.68 per diluted share, compared with USD 0.40 a year earlier, and adjusted Earnings Per Share rose 40% to USD 1.26.

Excluding Bausch + Lomb, revenue climbed 16% reported, and Operating Cash Flow was USD 517 million. The company raised its 2026 guidance for revenue, adjusted EBITDA and adjusted cash flows from operations, though the detailed ranges were not reviewed here.

The chief executive said net debt fell by one of the largest amounts since the 2022 refinancing. Earlier, the December 2025 Acquisition of Shibo's full-service aesthetics distribution business in China expanded the Solta and International reach.

What Investors Need to Watch Next

The next Quarterly Report should show whether raised guidance is achieved and how much net debt continues to decline.

Xifaxan performance, patent and litigation updates, Solta Medical growth and Bausch + Lomb margins are the most informative operating indicators.

Any steps involving the ownership of Bausch + Lomb or further debt transactions could alter the group's risk profile and the comparability of revenue per employee.

Shares fell 1.92% in the latest session. The stock's longer-term course is more likely to follow deleveraging, product durability and earnings delivery than the sales-per-employee ratio.